16-2076141-C-T
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM2PM5PP3_StrongPP5_Very_Strong
The NM_000548.5(TSC2):c.2713C>T(p.Arg905Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,568 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R905G) has been classified as Pathogenic.
Frequency
Consequence
NM_000548.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TSC2 | NM_000548.5 | c.2713C>T | p.Arg905Trp | missense_variant | 24/42 | ENST00000219476.9 | NP_000539.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TSC2 | ENST00000219476.9 | c.2713C>T | p.Arg905Trp | missense_variant | 24/42 | 5 | NM_000548.5 | ENSP00000219476 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461568Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 727094
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Tuberous sclerosis 2 Pathogenic:8
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 09, 2024 | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 905 of the TSC2 protein (p.Arg905Trp). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with tuberous sclerosis complex (PMID: 9463313, 12015165, 17120248, 19259131, 22867869). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 12404). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on TSC2 protein function. Experimental studies have shown that this missense change affects TSC2 function (PMID: 21309039). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant disrupts the p.Arg905 amino acid residue in TSC2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9829910, 17120248, 22867869, 25432535). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Oct 17, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Mar 22, 2023 | This variant is considered pathogenic. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 17120248, 29458892, 32917966, 14641237, 29196670]. Functional studies indicate this variant impacts protein function [PMID: 17120248, 21309039]. This variant is expected to disrupt protein structure [Myriad internal data]. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 01, 2009 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Sep 23, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 07, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetics and Molecular Pathology, SA Pathology | Dec 22, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Human Genetics, Inc, Center for Human Genetics, Inc | Nov 01, 2016 | - - |
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 17, 2021 | Published functional studies demonstrate a damaging effect on the TSC1-TSC2 complex (Hoogeveen-Westerveld et al. 2011); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 31447099, 25782670, 12015165, 19259131, 17304050, 14641237, 9463313, 22867869, 17120248, 22805177, 10205261, 23081885, 29196670, 31855466, 21309039) - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Aug 19, 2024 | PP3, PP4, PM2, PM5, PM6, PS3, PS4_moderate - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Tuberous sclerosis syndrome Pathogenic:1Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Apr 20, 2018 | The p.Arg905Trp variant in TSC2 has been previously reported in more than 25 ind ividuals with tuberous sclerosis complex, including at least one de novo occurre nce (TSC; Au 1998, Sancak 2005, Jansen 2006, Le Caignec 2009, Hoogeveen-Westerve ld 2011, van Eeghen 2013, Tuberous Sclerosis Project: http://tsc-project.partner s.org/index.htm, Tuberous sclerosis LOVD database: http://chromium.lovd.nl/LOVD2 /TSC) and has also been reported by other clinical laboratories in ClinVar (Vari ation ID: 12404). In vitro functional studies provide some evidence that the p. Arg905Trp variant may impact protein function (Jansen 2006, Hoogeveen-Westerveld 2011). This variant was absent from large population studies. Computational pr ediction tools and conservation analysis suggest that the p.Arg905Trp variant ma y impact the protein. Another variant at the same amino acid position (p.Arg905G ln) has been reported in individuals with TSC (Beauchamp 1998, Yamamoto 2002, Ja nsen 2006, van Eeghen 2013, Tyburczy 2015, Tuberous Sclerosis Project: http://ts c-project.partners.org/index.htm), suggesting that changes at this amino acid po sition are not tolerated. In summary, this variant meets criteria to be classif ied as pathogenic for TSC in an autosomal dominant manner based upon presence in multiple affected individuals, including a de novo occurrence, absence from the general population and functional and computational evidence. ACMG/AMP Criteria applied: PS4, PM6, PM2, PP3, PS3_Supporting. - |
not provided, no classification provided | curation | Tuberous sclerosis database (TSC2) | - | - - |
Lymphangiomyomatosis;C1846385:Isolated focal cortical dysplasia type II;C1860707:Tuberous sclerosis 2 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jun 30, 2021 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 22, 2022 | The p.R905W pathogenic mutation (also known as c.2713C>T), located in coding exon 23 of the TSC2 gene, results from a C to T substitution at nucleotide position 2713. The arginine at codon 905 is replaced by tryptophan, an amino acid with dissimilar properties. The p.R905W pathogenic variant has been reported as a recurrent de novo alteration in patients diagnosed with TSC (Au KS et al. Am. J. Hum. Genet., 1998 Feb;62:286-94; Jansen AC et al. Ann. Neurol. 2006 Nov;60(5):528-39; Le Caignec C et al. Eur. J. Hum. Genet., 2009 Sep;17:1165-70; http://www.lovd.nl/TSC2). Two additional mutations at codon 905 (p.R905Q and p.R905G) have been reported in numerous TSC families to date. Functional studies indicate that p.R905W disrupts tuberin activity and is pathogenic (Jansen AC et al. Ann. Neurol. 2006 Nov;60(5):528-39; Hoogeveen-Westerveld M et al. Hum. Mutat., 2011 Apr;32:424-35). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the available evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at